Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. (NYSE: ATR) generates news across drug delivery, digital health and consumer dispensing technologies. As a global company serving pharmaceutical, beauty, food, beverage, personal care and home care markets, its announcements often highlight new delivery systems, clinical collaborations, acquisitions and financial updates that are relevant to investors and industry observers.
Recent news has featured Aptar Pharma’s nasal and ophthalmic platforms, such as LuerVax and Spray Divider being used in a Phase II clinical trial of an intranasal COVID-19 vaccine candidate, and Bidose liquid nasal spray systems delivering an FDA-approved treatment for paroxysmal supraventricular tachycardia. The company also reports on developments in eye care, including its Beat the Blink technology and preservative-free multidose dispensers, as well as broader portfolios of ophthalmic solutions.
Aptar’s Digital Health division appears frequently in updates related to connected health tools and data-driven care. Examples include the integration of the Migraine Buddy app with biometric data from wearable devices and FDA 510(k) clearance for HeroTracker Sense, a connected add-on for metered-dose inhalers within a respiratory disease management platform.
Investors following ATR news will also find earnings releases, segment performance commentary, conference participation announcements and information on capital markets activity, such as senior notes offerings. This news page brings together these items so readers can review Aptar’s latest product milestones, partnerships, digital health initiatives and financial communications in one place.
Aptar (NYSE: ATR) announced a patented, reloadable airless packaging solution developed with Clarins for Total Eye Lift, claiming a 73% reduction in material impact per reload (50% less metal, 33% less plastic, 29% less cardboard). The Gaïa technology won a 2026 DIELINE award and is protected by two patents.
The design pairs a premium metal casing with plastic reloads to preserve formula protection, dispensing precision and luxury aesthetics while supporting product circularity and material efficiency.
Aptar (NYSE:ATR) reported Q1 2026 sales of $982.9M, up 11% year-over-year, with core sales flat. Reported net income was $73M and reported EPS $1.12; adjusted EPS was $1.19. Adjusted EBITDA margin was 19.2%. Returned $131M to shareholders. New CEO appointment effective September 1, 2026.
Segment strength included Beauty (+19%) and Injectables (+20%); Pharma core sales declined 1% with prescription dispensing down 10% due to emergency medicine destocking. Q2 adjusted EPS guidance: $1.32–$1.40.
Aptar (NYSE:ATR) launched an inverted lidless dispensing closure family for beauty and personal care on April 27, 2026, featuring its patented SimpliSqueeze® flow-control valve.
The design enables inverted, single-handed dispensing without a separate lid, aims to reduce drips and waste, and is already used on a pet shampoo line with extensions into home and hair care.
Aptar (NYSE: ATR) declared a quarterly cash dividend of $0.48 per share. The dividend is payable on May 27, 2026 to shareholders of record as of May 6, 2026.
The company will hold a conference call on May 1, 2026 at 8:00 a.m. CT to discuss first-quarter 2026 results; a live webcast and limited-time replay will be available on the investor website.
Aptar (NYSE: ATR) was named one of America’s Climate Leaders by USA Today for the fourth consecutive year on April 22, 2026. Aptar reports progress vs a 2019 baseline, SBTi-validated Scope 1 and 2 targets, CDP A List recognition, supplier engagement leadership, PPAs in Europe and the U.S.
Aptar Digital Health (NYSE: ATR) was named Enable Injections’ preferred digital health partner on April 8, 2026, to deliver a companion digital solution for the enFuse® On-Body Delivery System. The solution will guide patients through injection steps, capture adherence and patient-reported outcomes, and provide analytics dashboards to support clinical and commercial programs.
Built on a modular, scalable architecture, the platform is intended to support use cases from clinical trials through commercialization and enable pharmaceutical partners to integrate digital components into their programs.
Aptar (NYSE:ATR) announced its Unidose (UDS) Powder Nasal Spray System is being used in ENA Respiratory's Phase II study of investigational INNA‑051, with first participants dosed on March 19, 2026. The study evaluates safety, tolerability and potential effectiveness of a once‑weekly nasal spray for adults at increased exposure risk.
The UDS system supplies single, precise dry powder doses, modular moisture protection via a 3‑Phase Activ‑Polymer™ container closure, and internal safeguards against premature actuation to support clinical administration and formulation stability.
Aptar (NYSE:ATR) named Gael Touya as President and CEO effective September 1, 2026, succeeding Stephan B. Tanda, who will advise through year‑end and retire from the Board by end of 2026. The announcement highlights Gael’s 30+ years at Aptar and ~82% Aptar Pharma topline growth since 2018.
Stephan’s tenure (2017–2025) saw adjusted EBITDA expand from ~19% to ~22%, adjusted EPS +67%, and capital returned to shareholders up ~100%.
Aptar (NYSE:ATR) announced its proprietary multidose intranasal delivery system is being used in LTR Pharma's Phase II study of SPONTAN®, an investigational intranasal spray for erectile dysfunction. Aptar teams Nanopharm and Noble support formulation, analytical testing, human factors and risk management to advance clinical and regulatory readiness.
The announcement notes first-patient dosing in the Phase II study and emphasizes Aptar Pharma's role providing dosing accuracy, stability data and usability validation to support development.
Aptar (NYSE: ATR) will present at two investor conferences in early 2026. Stephan Tanda, President and CEO, will speak at the Bank of America Securities 2026 Global Agriculture and Materials Conference on Feb 25, 2026 at 9:45 a.m. ET. Vanessa Kanu, EVP and CFO, will speak at the Raymond James 2026 Institutional Investors Conference on Mar 3, 2026 at 1:05 p.m. ET. A live audio webcast and presentation materials will be available in the Investors section of the company website.